A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight
Launched by ELI LILLY AND COMPANY · Feb 10, 2025
Trial Information
Current as of May 07, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a medication called orforglipron, which is being tested to see how it can help adults with obesity or who are overweight lose body fat. The study will last about 8 months and aims to find out if orforglipron is more effective than a placebo, which is a sugar pill that doesn’t contain any active medication.
To participate, individuals must have a Body Mass Index (BMI) of 30 or higher, or a BMI of 27 or higher if they have other health issues related to being overweight. However, people with certain conditions like diabetes, unstable body weight, or liver disease, as well as those currently using other weight loss medications, cannot join the study. Throughout the trial, participants will be monitored closely to track their progress and any side effects. This research could help improve treatment options for people struggling with obesity.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Have a Body Mass Index (BMI)
- • ≥30.0 kilograms per square meter (kg/m2), or
- • ≥27.0 kg/m2 with comorbidities
- Exclusion Criteria:
- • Have type 1 diabetes, type 2 diabetes, or any other types of diabetes, history of ketoacidosis, or hyperosmolar state/coma
- • Have an unstable body weight within 90 days prior to screening
- • Have acute or chronic hepatitis
- • Are taking other medications or alternative remedies to manage weight loss
About Eli Lilly And Company
Eli Lilly and Company is a global healthcare leader dedicated to creating innovative medicines that improve patient outcomes across a range of therapeutic areas, including diabetes, oncology, immunology, and neurodegenerative diseases. With a rich history of scientific research and a commitment to advancing healthcare, Lilly invests significantly in clinical trials to develop new treatments and enhance existing therapies. The company prioritizes patient safety and ethical standards in its clinical research, fostering collaboration with healthcare professionals and stakeholders to ensure the delivery of high-quality, evidence-based solutions that address unmet medical needs worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Antonio, Texas, United States
Columbus, Ohio, United States
Dilworth, Minnesota, United States
Miami, Florida, United States
Patients applied
Trial Officials
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 : Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Eli Lilly and Company
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported